Reem Karmali

Medicine & Life Sciences

1. Lymphoma 100%
2. B-Cell Lymphoma 62%
3. Rituximab 61%
4. Mantle-Cell Lymphoma 56%
5. Survival 54%
6. Lymphoma, Large B-Cell, Diffuse 52%
7. Non-Hodgkin's Lymphoma 51%
8. Hodgkin Disease 47%
9. Progression-Free Survival 43%
10. Cell Transplantation 38%
11. Burkitt Lymphoma 30%
12. Follicular Lymphoma 28%
13. Therapeutics 28%
14. Treatment Failure 25%
15. Cachexia 23%
16. Recurrence 23%
17. Cyclophosphamide 19%
18. Homologous Transplantation 19%
19. Drug Therapy 19%
20. Brentuximab Vedotin 18%
21. Vincristine 17%
22. pembrolizumab 16%
23. Doxorubicin 15%
24. fludarabine 14%
25. Neoplasms 14%
26. B-Lymphocytes 14%
27. Transplants 14%
28. Central Nervous System 13%
29. TAK-659 13%
30. Stem Cell Transplantation 13%
31. Benchmarking 13%
32. Survival Rate 13%
33. Prednisone 11%
34. venetoclax 11%
35. Elderly 11%
36. Cytogenetics 11%
37. Chimeric Antigen Receptors 11%
38. Clinical Trials 9%
39. Allogeneic Cells 9%
40. ibritumomab tiuxetan 9%
41. Cell Survival 9%
42. Radioimmunotherapy 9%
43. Ferroptosis 9%
44. Activities of Daily Living 8%
45. Bendamustine Hydrochloride 8%
46. Multi-centric Castleman's Disease 8%
47. Agammaglobulinaemia Tyrosine Kinase 8%
48. Multicenter Studies 8%
49. Thiotepa 8%
50. Somatomedins 8%